National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

< Back to Main

Related Pages
Ovarian Cancer Home Page 1
NCI's gateway for information about ovarian cancer.

Search for Clinical Trials 2
NCI's PDQ® Cancer Clinical Trials Registry.
Ovarian Cancer Trial Results
1.  Modified Chemotherapy Regimen Effective in Advanced Ovarian Cancer 3
(Posted: 10/07/2009) - Women with advanced ovarian cancer had delayed disease progression and lived longer after receiving a modified regimen of a standard chemotherapy drug combination, according to an article published online Sept. 20, 2009, in The Lancet.

2.  Early Chemotherapy to Prevent Ovarian Cancer Recurrence Fails to Increase Survival 4
(Posted: 06/19/2009) - Women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose, according to findings presented at the 2009 ASCO meeting in Orlando.

3.  Removal of Ovaries and Fallopian Tubes Cuts Cancer Risk for BRCA1/2 Carriers 5
(Posted: 02/24/2009) - Surgery that removes the ovaries and fallopian tubes is one of the most effective ways to decrease a woman's risk of breast and gynecologic cancer if she carries a BRCA1 or BRCA2 gene mutation, according to the Jan. 21, 2009, Journal of the National Cancer Institute.

4.  Ultrasound Expertise Important in the Diagnosis of Ovarian Cancer 6
(Posted: 02/25/2008) - Improving the quality of diagnostic ultrasound scans could significantly reduce unnecessary surgeries in women with suspected ovarian cancer who, in fact, have benign disease, according to the February 2008 issue of the Lancet Oncology.

5.  Impact of Intraperitoneal Chemotherapy on Quality of Life During Ovarian Cancer Treatment 7
(Posted: 02/14/2007) - Women with ovarian cancer treated with intraperitoneal (IP)chemotherapy reported more side effects and a lower quality of life during their treatment compared to women receiving intravenous chemotherapy. However, at the end of one year, only neurological symptoms remained worse for the IP group, according to the Feb. 1, 2007, Journal of Clinical Oncology.
1 2 8 3 9   Next > 8


Table of Links

1http://www.cancer.gov/cancertopics/types/ovarian
2http://www.cancer.gov/clinicaltrials/search
3http://www.cancer.gov/clinicaltrials/results/dose-dense-chemo-ovarian1009
4http://www.cancer.gov/clinicaltrials/results/early-chemo-ovarian0609
5http://www.cancer.gov/clinicaltrials/results/BRCA0209
6http://www.cancer.gov/clinicaltrials/results/ovarian-ultrasound0208
7http://www.cancer.gov/clinicaltrials/results/IPchemo-QoL0207
8http://www.cancer.gov/clinicaltrials/results/ovarian?keyword=any+ovarian&page=2
9http://www.cancer.gov/clinicaltrials/results/ovarian?keyword=any+ovarian&page=3